# Meningococcal serogroups A, C, W, Y vaccine (MenACWY-D, MenACWY-CRM, MenACWY-TT) CDC recommendations- tabular CDSS rules (optimal)

Updated on 2024-04-24

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | | **MedIndication1** | | **MedIndication2** | | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | | **Todo5** | | | **Note-display** | | **Note** |
|  |  |  |  |  | **Y/N** | **Dose** | **Adm date** | |  | |  | |  |  |  |  |  | |  | | |  | |  |
| **MenACWY-D (Menactra), MenACWY-CRM (Menveo), MenACWY-TT (MenQuadfi)** |  |  |  |  |  |  |  | |  | |  | |  |  |  |  |  | |  | | |  | | MenACWY-D >= 9 mon; MenACWY-CRM >= 2 mon ; MenACWY-TT >= 2 yrs ; MenACWY vaccines are interchangable |
| **Regular and catch-up schedule** | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 1 | >=11 yrs | <=12 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose when age = 16 yrs |  |  | |  | | |  | |  |
|  | 2 | >=11 yrs | <= 12 yrs | With no ongoing risk of meningococcal disease | Y |  | At age of < 10 yrs | |  | |  | |  | Admin a dose | Schedule another dose when age = 16 yrs |  |  | |  | | |  | |  |
|  | 3 | >= 11 yrs | <= 12 yrs |  | Y |  | At age of =10 yrs | |  | |  | |  | Schedule a dose at age 16 yrs |  |  |  | |  | | |  | |  |
|  | 4 | = 16 yrs |  |  | Y |  | At age of <=12 yrs OR >= 8 wks from the most recent dose | |  | |  | |  | Admin 2nd dose |  |  |  | |  | | |  | |  |
|  | 5 | >=13 yrs | <= 15 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule a booster (>= 8 wks from now) AND (at age of 16-18 yrs) |  |  | |  | | |  | |  |
|  | 6 | >=13 yrs + 8 wks | <= 18 yrs |  | Y | 1 | At age 13-15 yrs or >= 8 wks from 1st dose | |  | |  | |  | Admin a booster dose |  |  |  | |  | | |  | |  |
|  | 7 | >= 16 yrs | <= 18 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose |  |  |  | |  | | |  | |  |
|  | 8 | >= 19 yrs | <= 21 yrs |  | Y |  | All at age < 16 yrs | |  | |  | |  | Admin one booster dose |  |  |  | |  | | |  | |  |
| **Special situations** | | | | | | | | | | | | | | | | | | | | | | | | |
| Menveo for persons with anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 9 | =2 mon |  |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose at age 4 mon | Schedule 3rd dose at age 6 mon | Schedule 4th dose 12 mon | |  | | |  | |  |
|  | 10 | >= 3 mon | <= 6 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from now | Schedule 3rd dose >= 8 wks if age < 7 mon | Schedule another dose >= 12 wks from 3rd dose AND age > 12 mon | |  | | |  | |  |
|  | 11 | >= 7 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks from 1st dose AND age > 12 mon |  |  | |  | | |  | |  |
|  | 12 | >= 24 mon | <16 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from the 1st dose |  |  | |  | | |  | |  |
| MenQuadfi for persons with anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 13 | >= 24 mon | <16 yr |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from 1st dose |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi for persons with anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 14 | >= 2 yrs | <7 yrs | If person remains at increased risk AND completes the primary vaccination | Y |  | Completion of primary vaccination |  | |  | |  | | Single dose at 3 yrs after final dose of primary vaccination | Booster dose every 5 yrs thereafter |  | |  | |  |  | |  | |
|  | 15 | >= 7 yrs | <=55 yrs | If person remains at increased risk AND completes the primary vaccination | Y |  | Completion of primary vaccination |  | |  | |  | | Single dose at 5 yrs after final dose of primary vaccination | Booster dose every 5 yrs thereafter |  | |  | |  |  | |  | |
| Menactra for persons with persistent complement component deficiency or complement inhibitor (e.g., eculizumab, ravulizumab) use | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 16 | >= 9 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks from 1st dose |  |  | |  | | |  | |  |
|  | 17 | >= 24 mon | < 16 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from 1st dose |  |  | |  | | |  | |  |
| Menactra for persons with anatomic or functional asplenia (including sickle cell disease), or HIV infection; | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 18 | >= 9 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Do not admin |  |  |  | |  | | |  | |  |
|  | 19 | >= 24 mon | < 16 yrs |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from the 1st dose |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi for microbiologists routinely exposed to isolates of Neisseria meningitidis | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 20 | >= 10 yrs |  | If person remains at increased risk | Y |  | Completion of primary vaccination OR MenQuadfi one dose | |  | |  | |  | Booster dose at 5 yrs after primary vaccination | Booster every 5 yrs thereafter |  |  | |  | | |  | |  |
| **Travel related vaccination recommendations** | | | | | | | | | | | | | | | | | | | | | | | | |
| Menveo for persons travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 21 | = 2 mon |  |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose at age of 4 mon | Schedule 3rd dose at age of 6 mon | Schedule 4th dose at age of 12 mon | |  | | |  | |  |
|  | 22 | >= 3 mon | <= 6 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from the 1st dose | Scheudle 3rd dose >= 8 wks when age > 7 mon | Schedule 4th dose >= 12 wks from 3rd dose AND age > 12 mon | |  | | |  | |  |
|  | 23 | >= 7 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks from 1st dose AND age > 12 mon |  |  | |  | | |  | |  |
| Menactra for persons travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 24 | >= 9 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi for persons travel in countries (or residents of countries) with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj | | | | | | | | | | | | | | | | | | | | | | | | |
|  | 25 | >=24 mon |  |  | N |  |  | |  | |  | |  | Admin 1 dose |  |  |  | |  | | |  | |  |
|  | 26 | <7 yrs |  | Persons remain in high risk | Y |  | Completion of primary vaccination OR MenQuadfi one dose | |  | |  | |  | Booster dose at 3 yrs after primary vaccination | Booster every 5 yrs thereafter |  |  | |  | | |  | |  |
|  | 27 | >=7 yrs |  | Persons remain in high risk | Y |  | Completion of primary vaccination OR MenQuadfi one dose | |  | |  | |  | Booster at 5 yrs after primary vaccination | Booster every 5 yrs thereafter |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi for persons who are at risk during an outbreak attributable to a vaccine serogroup | | | | | | | | | | | | | | | | | | | | | | | | |
| Menactra | 28 | >= 9 mon |  |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks from now |  |  | |  | | |  | |  |
| Menveo | 29 | = 2 mon |  |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose at age of 4 mon | Schedule 3rd dose at age of 6 mon | Schedule 4th dose at age of 12 mon | |  | | |  | |  |
| Menevo | 30 | >= 3 mon | <= 6 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from 1st dose | Schedule 3rd dose >= 8 wks when age > 7 mon | Schedule 4th dose >= 12 wks from 3rd dose AND age > 12 mon | |  | | |  | |  |
| Menveo | 31 | >= 7 mon | <= 23 mon |  | N |  |  | |  | |  | |  | Admin 1st dose | Schedule 2nd dose >= 12 wks from now AND at age > 12 mon |  |  | |  | | |  | |  |
| Menveo,  Menactra, MenQuadfi | 32 | >= 2 yrs | < 7 yrs | Being at increased risk | Y |  | Completion of primary vaccination OR MenQuadfi one dose | |  | |  | |  | Single booster if >= 3 yrs since the vaccination |  |  |  | |  | | |  | |  |
| Menveo,  Menactra, MenQuadfi | 33 | >= 7 yrs |  | Being at increased risk | Y |  | Completion of primary vaccination OR MenQuadfi one dose | |  | |  | |  | Single booster if >= 5 yrs since the vaccination |  |  |  | |  | | |  | |  |
| **College freshmen and military recruitment** | | | | | | | | | | | | | | | | | | | | | | | | |
| Menveo, Menactra, MenQuadfi | 34 | >= 16 yrs |  | First-year college students who live in residential housing or military recruits | N |  |  | |  | |  | |  | Admin 1 dose |  |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi | 35 | >=16 yrs |  | First-year college students who live in residential housing or military recruits | Y | 1 | < age of 16 yrs | |  | |  | |  | Admin 1 dose |  |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi | 36 | >=16 yrs |  | First-year college students who live in residential housing or military recruits | Y |  | At age of >= 16 yrs AND >= 5 yrs from now | |  | |  | |  | Admin 1 dose |  |  |  | |  | | |  | |  |
| Menveo, Menactra, MenQuadfi | 37 | >= 10 yrs |  | Military recruits | Y |  |  | | If high risk travel requirements | |  | |  | Booster every 5 yrs |  |  |  | |  | | |  | |  |
| **Timing with other vaccines** | | | | | | | | | | | | | | | | | | | | | | | | |
| Menactra (MenACWY-D) | 38 |  |  | DTaP |  |  |  | |  | |  | |  | Menactra should be administered before or at the same time of DTaP |  |  |  | |  | | |  | |  |
| Menactra (MenACWY-D) | 39 |  |  | Only if Menactra cannot be administered before or at the same time of DTaP |  |  |  | |  | |  | |  | Administered >= 6 mon after DTaP | No need to repeat dose |  |  | |  | | |  | |  |
| Menactra (MenACWY-D) | 40 |  |  | Only if Menactra cannot be administered before or at the same time of DTaP |  |  |  | | Child is at increased risk for meningococcal disease, e.g., travel | |  | |  | Administer regardless of DTaP |  |  |  | |  | | |  | |  |
| MenACWY | 41 |  |  | MenB |  |  |  | |  | |  | |  | May be administered simultaneously at different anatomic sites |  |  |  | |  | | |  | |  |
| Menactra | 42 |  |  | PCV13 series |  |  |  | |  | |  | |  | Menactra must be administered >= 4wks after completion of PCV13 series |  |  |  | |  | | |  | |  |
| **Contraindications and precautions** | | | | | | | | | | | | | | | | | | | | | | | | |
| Menveo, or Menactra, or MenQuadfi | 43 |  |  |  |  |  |  | | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | |  | |  | Do not admin |  |  |  | |  | | |  | | Contraindication |
| Menactra or Menveo | 44 |  |  |  |  |  |  | | Severe allergic reaction to any diphtheria toxoid- or CRM197-containing vaccine | |  | |  | Do not admin |  |  |  | |  | | |  | | Contraindication |
| MenQuadfi | 45 |  |  |  |  |  |  | | Severe allergic reaction to a tetanus toxoid-containing vaccine | |  | |  | Do not admin |  |  |  | |  | | |  | | Contraindication |
| Menveo | 46 |  |  |  |  |  |  | | Preterm birth if less than age 9 mon | |  | |  | Admin only if benefits outweigh risks to an adverse reaction |  |  |  | |  | | |  | | Precaution |
| Menveo, or Menactra, or MenQuadfi | 47 |  |  |  |  |  |  | | Moderate or severe acute illness with or without fever | |  | |  | Admin only if benefits outweigh risks to an adverse reaction |  |  |  | |  | | |  | | Precaution |